Aura Biosciences Inc (AURA)
NASDAQ:AURA
Want to see AURA full AI Analyst Report?
AURA Stock Chart & Stats
$7.29
-$0.11(-1.36%)
At close: 4:00 PM EST
$7.29
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$4.35 - $7.68
Previous CloseN/A
Volume82.15K
Average Volume (3M)295.85K
Market Cap
$432.06M
Enterprise Value$389.59M
Total Cash (Recent Filing)$144.24M
Total Debt (Recent Filing)$17.38M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding64,199,776
10 Day Avg. Volume355,322
30 Day Avg. Volume295,845
Financial Highlights & Ratios
PEG Ratio-5.42
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$20.67Price Target Upside183.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnrollmentAccelerated enrollment in the Phase 3 CoMpass trial could enable an earlier pivotal readout, reducing timing uncertainty around the choroidal melanoma program and potentially improving investor sentiment.
Formulation And Commercial ReadinessA room-temperature stable formulation that eliminates cold chain requirements could simplify in-office administration for urologists and support broader adoption across additional solid tumor indications.
Regulatory DesignationsFast Track and Orphan Drug designations together with a Special Protocol Assessment provide regulatory support that may streamline development and increase the probability of a favorable review.
Bears Say
Cash RunwayHigh annualized cash burn implies a limited cash runway that may require the company to seek new funding, risking dilution for existing shareholders.
Financing Terms RiskNear-term financing needs could force capital raises on unfavorable terms, increasing the company’s cost of capital and compressing upside for current investors.
Program Execution RiskUrgent fundraising pressure could divert management focus and resources, increasing the risk of delays in trial enrollment and key clinical milestones.
Aura Biosciences Inc News
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $4.34 and its highest was $7.68 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $432.06M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is May 07, 2026 which is in 6 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Mar 30, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.428 by $0.088.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 64,199,776 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.428. Following the earnings report the stock price went down -1.116%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aura Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (183.49% Upside)
$20.67 (183.49% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $611.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.00%
12-Months-Change
Fundamentals
Return on Equity
-71.25%
Trailing 12-Months
Asset Growth
75.33%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
AURA Stock 12 Month Forecast
Average Price Target
$20.67
▲(183.49% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
3.07% Insiders
8.33% Mutual Funds
4.88% Other Institutional Investors
75.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---